Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: Structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109

Journal of Medicinal Chemistry

Volumn 49, Issue 15, 2006, Pages 4721-4736

  Hirashima, Shintaro ^a   Suzuki, Takayoshi ^a,b   Ishida, Tomio ^a   Noji, Satoru ^a   Yata, Shinji ^a   Ando, Izuru ^a   Komatsu, Masakazu ^a   Ikeda, Satoru ^a   Hashimoto, Hiromasa ^a,b  

^a JAPAN TOBACCO INC   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [4' CHLORO 4 (2 OXOPYRROLIDIN 1 YL)BIPHENYL 2 YLMETHOXY] 2 FLUOROPHENYL] 1 CYCLOHEXYL 1H BENZIMIDAZOLE 5 CARBOXYLIC ACID; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; HCV 796; JTK 109; PEGINTERFERON; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; RNA DIRECTED RNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VALOPICITABINE;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG SAFETY; DRUG STRUCTURE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; RAT; REPLICON; RNA REPLICATION; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; CELL LINE; CELL SURVIVAL; HEPACIVIRUS; HUMANS; LIVER; RATS; REPLICON; RNA REPLICASE; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

EID: 33746700189     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060269e     Document Type: Article

References (31)

1. Ishida, T.; Suzuki, T.; Hirashima, S.; Mizutani, K.; Yoshida, A.; Ando, I.; Ikeda, S.; Adachi, T.; Hashimoto, H. Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: Identification of 2-[(4-diarylmethoxy)phenyl]- benzimidazole. Bioorg. Med. Chem. Lett. 2006, 16, 1859-1863.
2. Hashimoto, H.; Mizutani, K.; Yoshida, A. Preparation of Heterocyclic Compounds as Remedies for Hepatitis C. Int. Patent Appl. WO 01/47883, 2001.
3. Choo, Q, L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244, 359-362.
4. Bartenschlager, R. Candidate targets for hepatitis C virus-specific antiviral therapy. Intervirology 1997, 40, 378-393.
5. WHO. Global surveillance and control of hepatitis C. J. Viral Hepatitis 1999, 6, 35-47.
6. Takahashi, M.; Yamada, G.; Miyamoto, R.; Doi, T.; Endo, H.; Tsuji, T. Natural course of chronic hepatitis C. Am. J. Gastroenterol. 1993, 88, 240-243.
7. Fried, M. W.; Shiffman, M. L.; Reddy, K. R.; Smith, C.; Marinos, G.; Gonçales, F. L., Jr.; Häussinger, D.; Diago, M.; Carosi, G.; Dhumeaux, D.; Craxi, A.; Lin, A.; Hoffman, J.; Yu, J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347, 975-982.
8. Reviews: (a) Tan, S. L.; Pause, A.; Shi, Y.; Sonenberg, N. Hepatitis C therapeutics: Current status and emerging strategies. Nat. Rev. Drug Discovery 2002, 1, 867-881.
9. (b) Beaulieu, P. L.; Tsantrizos, Y. S. Inhibitors of the HCV NS5B polymerase: New hope for the treatment of hepatitis C infections. Curr. Opin. Invest. Drugs 2004, 5, 838-850.
10. (c) Gordon, C. P.; Keller, P. A. Control of hepatitis C: A medicinal chemistry perspective. J. Med. Chem. 2005, 48, 1-20.
11. (d) De Francesco, R.; Migliaccio, G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005, 436, 953-960.
12. Kolykhalov, A. A.; Mihalik, K.; Feinstone, S.; Rice, C. M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J. Virol. 2000, 74, 2046-2051.
13. (a) Beaulieu, P. L.; Bousquet, Y.; Gauthier, J.; Gillard, J.; Marquis, M.; McKercher, G.; Pellerin, C.; Valois, S.; Kukolj, G. Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: Inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 Cells. J. Med. Chem. 2004, 47, 6884-6892.
14. (b) Beaulieu, P. L.; Bös, M.; Bousquet, Y.; Fazal, G.; Gauthier, J.; Gillard, J.; Goulet, S.; LaPlante, S.; Poupart, M.-A.; Lefebvre, S.; McKercher, G.; Pellerin, C.; Austel, V.; Kukolj, G. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: Discovery and preliminary SAR of benzimidazole derivatives. Bioorg. Med. Chem. Lett. 2004, 14, 119-124.
15. Harper, S.; Avolio, S.; Pacini, B.; Di Filippo, M.; Altamura, S.; Tomei, L.; Paonessa, G.; Di Marco, S.; Carfi, A.; Giuliano, C.; Padron, J.; Bonelli, F.; Migliaccio, G.; De Francesco, R.; Laufer, R.; Rowley, M.; Narjes, F. Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase. J. Med. Chem. 2005, 48, 4547-4557.
16. Tedesco, R.; Shaw, A. N.; Bambal, R.; Chai, D.; Concha, N. O.; Darcy, M. G.; Dhanak, D.; Fitch, D. M.; Gates, A.; Gerhardt, W. G.; Halegoua, D. L.; Han, C.; Hofmann, G. A.; Johnston, V. K.; Kaura, A. C.; Liu, N.; Keenan, R. M.; Lin-Goerke, J.; Sarisky, R. T.; Wiggall, K. J.; Zimmerman, M. N.; Duffy, K. J. 3-(1,1-Dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones. Potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase. J. Med. Chem. 2006, 49, 971-983.
17. Afdhal, N.; Godofsky, E.; Godofsky, B.; Dienstag, J.; Rustgi, V.; Schick, L.; McEniry, D.; Zhou, X.-J.; Chao, G.; Fang, C.; Fielman, B.; Myers, M.; Brown, N. Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: Antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Presented at the 55th AASLD, Boston, MA, October 29 through November 2, 2004; http://www.idenix.com/products/ datapres_nm283/AfdhalAASLD04_10-04.pdf.
18. Company Press Release, ViroPharma, Inc., November 10, 2005; http://phx.corporate-ir.net/phoenix./html?c=92320&p= irol- researchNewsArticle&ID=781310&highlight=HCV.
19. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2457-2483.
20. Clarke, H. T.; Gillespie, H. B.; Weisshaus, S. Z. The action of formaldehyde on amines and amino acids. J. Am. Chem. Soc. 1933, 55, 4571-4587.
21. Nahm, S.; Weinreb, S. M. N-Methoxy-N-methylamides as effective acylating agents. Tetrahedron Lett. 1981, 22, 3815-3818.
22. Suzuki, M.; Iwasaki, T.; Miyoshi, M.; Okumura, K.; Matsumoto, K. New convenient synthesis of α-C-acylamino acids and α-amino ketones. J. Org. Chem. 1973, 38, 3571-3575.
23. Pedersen, B. S.; Lawesson, S.-O. Studies on organophosphorus compounds. XXVIII. Syntheses of 3H-1,2-dithio1e-3-thiones and 4H-1,3,2-oxazaphosphorine derivatives from the dimer of p-methoxyphenylthionophosphine sulfide and derivatives of 3-oxo carboxylic acids. Tetrahedron. 1979, 35, 2433-2437.
24. Sato, T.; Itoh, H.; Fujiwara, T. Facile synthesis of β-ketoesters by a coupling reaction of the Reformatsky reagent with acyl chlorides catalyzed by palladium complex. Chem. Lett. 1982, 1559-1560.
25. Schenone, P.; Sansebastiano, L.; Mosti, L. Reaction of 2-dimethyl-aminomethylene-1,3-diones with dinucleophiles. VIII. Synthesis of ethyl and methyl 2,4-disubstituted 5-pyrimidinecarboxylates. J. Heterocycl. Chem. 1990, 27, 295-305.
26. Adachi, T.; Ago, H.; Habuka, N.; Okuda, K.; Komatsu, M.; Ikeda, S.; Yatsunami, K. The essential role of C-terminal residues in regulating the activity of hepatitis C virus RNA-dependent RNA polymerase. Biochim. Biophys. Acta 2002, I601, 38-48.
27. Lohmann, V.; Körner, F.; Koch, J. O.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285, 110-113.
28. Krieger, N.; Lohmann, V.; Bartenschlager, R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 2001, 75, 4614-4624.
29. A similar observation is seen in the structurally related indole series. See ref 11.
30. The Boehringer Ingerheim group reported in their study of benzimidazole derivatives that the aromatic ring at the 2-position of the benzimidazole ring sterically influences the conformation of the cyclohexyl ring at the N′-position and that steric bulkiness at the ortho position reduces the biochemical potency. See ref 10b.
31. Cory, A. H.; Owen, T. C.; Barltrop, J. A.; Cory, J. G. Use of an aqueous soluble terazolin/formazan assay for cell growth assays in culture. Cancer Commun. 1991, 3, 207-212.